Max Tejada

Kite, a Gilead Company

Max Tejada is a scientist with 20+ years of experience at Genentech, Gilead, AstraZeneca and Kite where he has led teams focused on the development, validation, and transfer of bioassay or immunoassays for therapeutic proteins, monoclonal antibodies, antibody drug conjugates and cell based cancer immunotherapies. He has led analytical and Chemistry Manufacturing and Controls (CMC) teams for investigational oncology and immunotherapy programs and has been a contributing author on numerous regulatory filings in both early and late clinical phases. Max obtained his Ph.D. in Biochemistry from Queen’s University in Kingston, Ontario, Canada. He was a post-doctoral fellow in the laboratory of Dr. Napoleone Ferrara at Genentech.